SMAD7 Polyclonal Antibody
Price: $ 530
Price: $ 320
Price: $ 200
- Host: Rabbit
- Reactivity: Human;Mouse;Rat
- Applications: WB;IF
For research use only. Order now, ship in 3 days
Verified Samples |
Verified Samples in WB:Mouse kidney,Mouse liver,Rat kidney,Rat liver Verified Samples in IF: U2OS |
Dilution |
WB 1:500-1:2000, IF 1:50-1:200 Western Blot Operation Guide |
Clonality | Polyclonal |
Immunogen | A synthetic peptide of human SMAD7 (NP_005895.1). |
Abbre | SMAD7 |
Synonyms | SMAD7;CRCS3;MADH7;MADH8 |
Swissprot | |
Calculated MW | 23kDa/46kDa |
Observed MW |
46kDa
The actual band is not consistent with the expectation.
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
Cellular Localization | Nucleus. Cytoplasm. Interaction with NEDD4L or RNF111 induces translocation from the nucleus to the cytoplasm (PubMed:16601693). TGF-beta stimulates its translocation from the nucleus to the cytoplasm. PDPK1 inhibits its translocation from the nucleus to the cytoplasm in response to TGF-beta (PubMed:17327236). |
Concentration | 1mg/mL |
Buffer | PBS with 0.02% sodium azide, 50% glycerol, pH7.3. |
Purification Method | Affinity purification |
Research Areas | Cancer; Epigenetics and Nuclear Signaling; Signal Transduction |
Conjugation | Unconjugated |
Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
Shipping | Ice bag |
background | The protein encoded by this gene is a nuclear protein that binds the E3 ubiquitin ligase SMURF2. Upon binding, this complex translocates to the cytoplasm, where it interacts with TGF-beta receptor type-1 (TGFBR1), leading to the degradation of both the encoded protein and TGFBR1. Expression of this gene is induced by TGFBR1. Variations in this gene are a cause of susceptibility to colorectal cancer type 3 (CRCS3). Several transcript variants encoding different isoforms have been found for this gene. |